Research programme: 3-phosphoinositide-dependent kinase-1 inhibitors - Bayer HealthCare Pharmaceuticals

Drug Profile

Research programme: 3-phosphoinositide-dependent kinase-1 inhibitors - Bayer HealthCare Pharmaceuticals

Alternative Names: BX-320; BX-517; BX-795; BX-912; PDK1 inhibitors - Bayer HealthCare Pharmaceuticals

Latest Information Update: 23 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Berlex Biosciences
  • Class
  • Mechanism of Action 3 phosphoinositide dependent protein kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 04 Apr 2007 Berlex is now called Bayer HealthCare Pharmaceuticals
  • 20 May 2005 A preclinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top